Prescriptions for more than doubled in one week monoclonal antibodies against Covid 19 in Italy. After a progressively decreasing trend, the trend seems to have reversed in the last 7 days monitored by the Italian drug agency Aifa: from 34 drug requests (Rf) in the period 25 June-1 July, between 2 and 8 July has passed to 74 Rf. Daily average 10.57 versus 4.86, an increase of 118%.
They thus rise to 6,198 Covid patients treated with monoclonal antibodies in our country, and entered in the specific Aifa monitoring register. From 10 March, when these medicines were authorized as an emergency in Italy for particularly fragile people with recent Sars-CoV-2 infection and without severe symptoms, to 8 July, 195 structures in 21 Regions or Autonomous Provinces have they prescribed these therapies.
To date, the majority of treated patients (3,450) have received the combination of the two antibodies bamlanivimab and etesevimab, followed by the mix casirivimab-imdevimab (1,924).
Since the start of monitoring, in absolute numbers Lazio remains the region with the greatest use with 838 patients treated, followed by Veneto with 803 patients and Tuscany with 752, while in the last places there are Molise and the Autonomous Province of Bolzano, respectively with 13 and 3 patients entered in the registry. In the last week analyzed, the highest number of prescriptions was reported by Sicily (15), followed by Veneto (14) and Lazio (9).
Looking at the drug requests activated with respect to the new positives recorded, the national prevalence figure is 1.2% (74 Rf in the last week out of 6,325 new positives). Calabria (3.2%), Veneto (2.6%), Basilicata and Tuscany (1.8%), Sicily (1.7%), Emilia Romagna (1.6%) and Lazio are above the national average. (1.5%).